CYP3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in HIV-1 infected adults. Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] Journal article | | Title | CYP3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in HIV-1 infected adults. | | Author(s) | von Hentig N, Lötsch J | | Institution | pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany; HIVCENTER, Medical HIV Research and Treatment Unit, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany. | | Source | Antimicrob Agents Chemother 2009 Jun 15. | | Abstract | Inadequate concentrations of the HIV protease inhibitor saquinavir jeopardize the individual therapy success or produce side effects despite treatment according to the current guidelines. We performed a population pharmacokinetic analysis with NONMEM and indentified that steady-state saquinavir pharmacokinetics in 136 HIV-1 infected adults were modulated by a decrease in saquinavir clearance following co-administration of CYP3A inhibitors ritonavir and atazanavir. In contrast, age, sex, weight, pregnancy or the pharmaceutical formulation exerted only minor non-significant effects. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19528289 |
|
|
| |
Advertise on this site.
| | |
|
